Abstract
Here we describe a 16-year-old patient suffering from an acute withdrawal syndrome with gamma-butyrolactone (GBL), a designer drug with increasing case numbers describing acute abuse, life threatening withdrawal or overdose complications. Acute management along with complications as regards vegetative adverse reactions to treatment are presented and briefly discussed. To the best of our knowledge this is the youngest case of severe GBL withdrawal syndrome reported so far in the available literature.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
